Close Menu

NEW YORK – AI precision medicine firm Tempus said on Tuesday that it has obtained the CE mark for its cancer genomic sequencing assay, xT, making the test available for clinical use in Europe and other countries that accept the designation.

According to the company, the xT assay is already used by thousands of oncologists in the US, and broadening availability to European clinicians is part of the firm's regulatory strategy.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.